C4X Discovery’s £1.67m purchase of Adorial provides access to a technology platform that should enable C4X to accelerate the identification of novel drug targets and associated development of small molecule drugs. The deal complements C4X’s rational drug design technology and fits its strategic ambition of becoming a highly efficient and productive drug discovery engine, targeting up to 15 new development projects over the next three years.
